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Background: Prescription opioid analgesic (POA) utilization has steeply increased globally, yet is far higher in
established market economies than elsewhere. Canada features the world’s second-highest POA consumption rates.
Following increases in POA-related harm, several POA control interventions have been implemented since 2010.
Methods: We examined trends and patterns in POA dispensing in Canada by province for 2005–2012, including a
focus on the potential effects of interventions. Data on annual dispensing of individual POA formulations –
categorized into ‘weak opioids’ and ‘strong opioids’ – from a representative sub-sample of 5,700 retail pharmacies
across Canada (from IMS Brogan’s Compuscript) were converted into Defined Daily Doses (DDD), and examined
intra- and inter-provincially as well as for Canada (total).
Results: Total POA dispensing – driven by strong opioids – increased across Canada until 2011; four provinces
indicated decreases in strong opioid dispensing; seven provinces indicated decreases specifically in oxycodone
dispensing, 2011–2012. The dispensing ratio weak/strong opioids decreased substantively. Major inter-provincial
differences in POA dispensing levels and qualitative patterns of POA formulations dispensed persisted. Previous
increasing trends in POA dispensing were reversed in select provinces 2011–2012, coinciding with POA-related
interventions.
Conclusions: Further examinations regarding the sustained nature, drivers and consequences of the recent trend
changes in POA dispensing – including possible ‘substitution effects’ for oxycodone reductions – are needed.
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The global utilization of prescription opioid analgesics
(POAs) – principal medications for pain care – has
sharply increased in recent years. For example, the pro-
duction of morphine doubled 1992–2011, and the pro-
duction of oxycodone tripled 2002–2011 [1]. However,
the global distribution of POA utilization is highly in-
equitable [2,3]. About 90% of all POAs are consumed in
established market economies (EMEs), and >80% of the
world’s population – mainly in low or middle income* Correspondence: bfischer@sfu.ca
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unless otherwise stated.countries – have no or inadequate access to POAs, even
though they have most of the world’s cancer and HIV
patients [3]. Even within EMEs, North America – i.e.,
the United States [51,081 Defined Daily Doses per
1,000,000 population (DDD) in 2009–11], and Canada
[28,731 DDD] – features far higher rates of POA
utilization than any other global region [1,4]. For com-
parison, North America’s POA consumption rates are
more than double those of the European Union or the
Australia/New Zealand regions, and hundreds of times
those of China or India. The disproportionately high
POA use levels in North America have been explained
by a multiplicity of drivers, including a strong focus on
pharmacotherapeutic interventions, laxer regulatory
frameworks, aggressive pharmaceutical advertising and
commodification of health care, together contributing toLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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interventions are commonly privileged by providers and
desired by patients over other interventions [5-8].
The high and rising POA use rates specifically in
Canada – similar to the US – have been paralleled by
substantive levels of POA-related morbidity and mortal-
ity [4]. In Ontario, some 6% of adults, and 15% of high-
school students reported non-medical POA use in 2010/
2011; POA-related substance use treatment admissions
more than doubled, and POA-related overdose deaths
more than tripled since 2002 [4,9-13]. Levels of POA
availability have been shown to be strongly correlated
with levels of POA-related morbidity and mortality,
hence constituting a principal driver for POA-related
harm on a population level [10,14-17].
A recent examination of POA dispensing – an imper-
fect yet measurable and best available indicator of POA
consumption on a population level - in Canada in
2005–2010 found that [18]: 1) Most provinces featured
increases in overall POA use levels; 2) increases were
predominantly driven by increases in strong (versus
weak, i.e. non-codeine versus codeine-based POA for-
mulations) POA use; 3) there were considerable quanti-
tative (i.e., overall POA use levels) and qualitative (i.e.,
individual POA types used) inter-provincial differences;
in most provinces, oxycodone (e.g., Oxycontin®) consti-
tuted the most commonly consumed single ‘strong
opioid’ formulation, and most strongly contributed to
POA use increases.
Beginning in 2010, rising POA use and harm levels in
Canada began to receive increasing attention from key
policy, professional and mass media entities; many of
these focused on Oxycontin®, associated with a large
proportion of POA-related harm [4,11,19]. For example,
the Ontario College of Physicians and Surgeons’ report
‘Avoiding Abuse, Achieving a Balance: Tackling the
Opioid Public Health Crisis’ (2010) presented recom-
mendations to reduce POA misuse and diversion; a
multi-disciplinary workgroup launched the ‘Canadian
Guidelines for Safe and Effective Use of Opioids for
Chronic Non-Cancer Pain’ (2010); a high-profile coro-
ners’ inquest into a series of POA-related deaths in On-
tario (2011) made recommendations for improved POA
controls; and the government of Ontario’s ‘Narcotics Ex-
pert Advisory Panel’ (2011) conveyed recommendations
towards reduced POA-related misuse and harm [20-23].
These included, as a key policy measure, the delisting of
Oxycontin® (together with its successor product, Oxy-
Neo®), the principally common oxycodone formulation,
from Ontario’s provincial drug formulary as of March
2012; this measure was replicated by the majority of
other but not all provinces (e.g., Alberta) [23-25]. ‘Delist-
ing’ meant that provincially funded drug plans (e.g.,
covering individuals receiving public welfare, disabilityor seniors’ benefits; the Ontario Drug Benefit (ODB)
plan covers about 20% of the Ontario population) would
not pay for these oxycodone formulations any longer, al-
though these may still be prescribed to patients with pri-
vate drug plans and/or paying out of pocket. In addition,
key media outlets ran numerous prominent feature re-
ports on increases in POA utilization, harm and policy
challenges in Canada in this period [26-30].
The objective of this study was to provide an update
of POA dispensing trends and patterns, by province, for
the period 2005–2012, with specific consideration of re-
cent POA-focused interventions in Canada.
Methods
The present analyses are based on data for dispensing of
POAs from retail pharmacies in Canada (meaning here:
the total of the ten provinces, not including territories)
for the period January 2005 to December 2012, obtained
from the IMS Brogan’s (IMSB’s) Canadian CompuScript
Audit [31]. It is estimated that about 80% – i.e., the large
majority – of the total of POAs are dispensed by way of
retail pharmacies (other main routes include hospital- or
emergency care-based dispensing which are not cap-
tured in these data) [18]. The IMSB’s CompuScript panel
is drawn from a representative and stratified base sample
of 5,700 retail pharmacies (representing about two-
thirds of the total of retail pharmacies) across Canada,
from which a continuously refreshed sub-sample of 65%
are providing pharmaceutical dispensing data on a
monthly basis [31,32]. Following quality control checks,
IMSB projects the sample data to the universe of phar-
macies by province; the sampling error is estimated to
be 3%–5%. Given the sampling approach described, the
level of representativeness of IMSB data for the actual
total of POAs dispensed by retail pharmacies in Canada
is considered high.
Monthly dispensing data on all POA types were aggre-
gated to the yearly data. Methadone was excluded from
the analyses since it is primarily used for addiction (i.e.,
opioid maintenance) treatment, and only in less com-
mon instances for pain treatment; this results in irregu-
lar dispensing patterns, as a substantial proportion of
methadone is dispensed not by retail pharmacies, and
therefore non-comparable data with other POs for the
purposes of the present study. Data on the different
POA types dispensed in Canada during the study period
were converted to DDD values – the assumed average
maintenance dose per day for a drug used for its main
indication for an average adult – according to the World
Health Organization’s (WHO) Anatomical Therapeutic
Chemical (ATC) classification and DDD measurement
methodology [33,34]. Furthermore, based on the WHO’s
pain ladder, codeine and its combination products
were defined as ‘weak opioids' , whereas hydrocodone,
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morphine formulations were defined as ‘strong opioids’
for the purpose of combination analysis [35]. On this
basis, and applying corresponding provincial population
estimates from Statistics Canada [36], the annual dis-
pensing rates for each PO, as well as for ‘weak POs’ and
‘strong POs’ were calculated for each province, as well as
the Canada total, as the number of DDDs per 1000
population/day, and compared inter-jurisdictionally and
over-time. As an additional indicator, we calculated the
annual provincial ratios of dispensing of weak POs/
strong POs for the years 2005 and 2012 each. Changes
in the ratios (10 pairs) were tested for significance by
McNemar test.
Results
Throughout each year of the study period, Alberta fea-
tured the highest, and Quebec had the lowest total POA
dispensing levels; there was a greater than 3-fold differ-
ence in annual total POA dispensing between these two
provinces. In all but one province (Ontario), annual total
POA dispensing (i.e., weak and strong POAs combined)
increased from 2005 to 2012; four provinces (BC, AB,
SK, ON; see Table 1 for list of provinces’ full names)
indicated a decrease in overall POA dispensing levels
in 2011–2012. While strong POA dispensing increased
substantively in each province between 2005 and 2011,
four provinces (BC, AB, MN, ON) indicated decreases
in 2011–2012. Dispensing of oxycodone formulations –
as a specific sub-group of strong opioids – increased in
all provinces 2005–2011, yet decreased in seven prov-
inces 2011–2012. Weak opioid dispensing remained
overall levelled – except for Manitoba, which featured
substantive increases – in most provinces 2005–2012.Table 1 Annual change rates and ratios for opioid dispensing i
Change rate (%) in
Strong opioids Weak opi
Province 2005-2011 2011-2012 2005-2011 2
British Columbia (BC) +48.5 −2.0 −3.8
Alberta (AB) +29.3 −3.9 −0.4
Saskatchewan (SK) +98.7 +1.2 +26.2
Manitoba (MN) +98.2 −2.9 +37.4
Ontario (ON) +39.5 −15.2 −12.3
Quebec (QC) +45.4 +2.9 −5.4
New Brunswick (NB) +39.0 +1.2 −0.7
Nova Scotia (NS) +43.5 +2.7 −4.6
Prince Edward Island (PE) +62.8 +6.0 −3.8
Newfoundland (NL) +71.8 +5.2 −1.3
Canada (CA) +43.4 −7.9 −3.3
Annual change rates for ‘strong opioid’, ‘weak opioid’ and ‘oxycodone’ dispensing (
(2005 and 2012), by province and Canada total.The ratio of weak/strong POA dispensing decreased for
each province between the years 2005 and 2012; while
this ratio was 1 or greater for all provinces in 2005, it
was 1 or smaller for half the provinces in 2012. These
changes overall approached but did not reach statistical
significance (exact McNemar’s test p-value: 0.0625).
Figures 1 and 2 focusing on individual (strong) POA
formulations and comparing the years 2005 to 2012, fen-
tanyl dispensing increased in all provinces, and was
highest in Ontario (both years), and lowest in Prince
Edward Island (2005) and Newfoundland (2012). Hydro-
codone dispensing decreased in most provinces, yet
was far higher in Ontario than any other province (both
years), and lowest in Manitoba (2005) and Alberta (2012).
Hydromorphone dispensing consistently increased in all
provinces, and was highest in Nova Scotia and lowest in
Newfoundland (both years, respectively). Meperidine dis-
pensing decreased in the majority of provinces, and was
highest in Newfoundland and lowest in Manitoba (both
years). Morphine dispensing increased and decreased in
about half of the provinces, respectively, and was highest
in British Columbia (2005) and Newfoundland (2012), and
lowest in Quebec (both years). Oxycodone dispensing was
highest in Ontario (both years) and lowest in Quebec
(2005) and Nova Scotia (2012; for over-time dispensing
trends for oxycodone see above).
Discussion
First, our analyses extend observations about key pat-
terns and trends in POA dispensing in Canada observed
in earlier examinations [18]. Concretely, POA dispensing
levels substantively increased in the study period, except
for notable decreases between 2011 and 2012 (see
also below). The observed previous increases in POAn Canada, by province and for Canada (total), 2005–2011
dispensing Opioid dispensing ratio
oids Oxycodone Weak/Strong
011-2012 2005-2011 2011-2012 2005 2012
−1.6 +135.0 −9.0 2.7 1.8
+1.7 +64.7 −9.7 2.8 2.2
−3.4 +88.2 −18.1 1.5 0.9
+3.0 +118.2 −11.5 4.2 3.1
−7.7 +75.2 −24.4 1.4 0.9
−2.2 +88.5 +0.6 1.0 0.6
+0.1 +56.9 −8.4 1.5 1.1
−2.6 +29.1 −9.7 1.3 0.8
−3.2 +98.4 +2.1 1.8 1.0
+5.0 +93.3 +2.0 2.5 1.5
−2.8 +80.4 −17.2 1.7 1.2
2005–2011 and 2011–2012) and annual dispensing ratios weak/strong opioids
Figure 1 Annual opioid dispensing (not including methadone) in Canada, 2005–2012. Annual opioid dispensing (not including methadone),
by weak opioids and strong opioids, in DDD/1000 population/day by province and Canada total, 2005–2012. Bars are chronological for years
2005–2012. For full names of provinces, see Table 1. CA represents Canada (total).
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opioids’ dispensing; consequently, half of the provinces
(in DDDs) dispensed more ‘strong opioids’ than ‘weak
opioids’ in 2012. Furthermore, considerable inter-provincial
heterogeneity between the provinces regarding quantities
and types of individual POs dispensed continued, including
the remarkably substantive (i.e., three-fold) differences in
POA dispensing levels between the highest (Alberta) and
lowest (Quebec) province. It may be assumed that – similar
to explanations of differences in POA utilization on inter-
national levels – the inter-provincial quantitative and quali-
tative differences in POA utilization observed in Canada
are a result of a multitude of factors, including key differ-
ences in drug regulation or formularies, monitoring and es-
pecially reimbursement schemes (all of which are set
independently on provincial levels) as well as details of
medical culture and practice [6,37-39]. Our observations
are set in the context of Canada where utilization levels of
other key psychotropic drugs (e.g., benzodiazepines, anti-
depressants) have also substantively increased in recentyears (e.g., 1998–2007), yet also display considerable inter-
provincial differences in levels (e.g., up to two-fold) [40].
While global increases in POA utilization have been ratio-
nalized with urgent needs to improve health care, especially
for chronic pain, it remains unclear whether Canada is
home to higher levels of pain or addresses pain more ef-
fectively than comparable nations with substantially lower
POA utilization levels; this question continues to be pre-
eminent given the mixed evidence on the efficacy of POAs
in the treatment of pain [2,41-44].
Notable changes in POA dispensing trends in Canada,
however, occurred between 2011 and 2012, when overall
POA – and specifically ‘strong opioid’ – dispensing sud-
denly decreased in several provinces. The largest propor-
tion of these reductions (>80%) related to reductions in
oxycodone dispensing – the POA formulations that had
constituted the largest share of ‘strong opioid’ dispens-
ing to date and has been associated with a dispropor-
tionate amount of POA-related harm in most provinces
[4,18,19]. Reductions in oxycodone dispensing (24% in














































































































































































Figure 2 Annual dispensing of select strong opioids in Canada, 2005–2012. Annual dispensing of select strong opioids, in DDD per 1000
population/day, by province and Canada total, 2005–2012. Bars are chronological for years 2005–2012. For names of provinces, see Table 1. CA
represents Canada (total).
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the previously highest oxycodone utilization levels in
Canada – where total POA dispensing in 2012 was con-
sequently reversed to below-2005 levels [18]. These
trend-reversing developments in POA dispensing oc-
curred following – and are likely related to – a variety of
recent interventions aiming at improved POA use regu-
lation and control, most prominently including the
‘delisting’ of Oxycontin® (effective March 2012) from the
majority of provincial drug formularies [23-25]. Notably,
reductions in oxycodone dispensing were not observed
in several of the jurisdictions where Oxycontin® was also
delisted, yet equally occurred in a province (Alberta)
where delisting did not occur. Also given that the
present study period captured only a small timeframe
(<1 year) following the delisting of Oxycontin®, it re-
mains to be evaluated what further trends and possible
changes in POA utilization may follow the above inter-
ventions, yet also what factors may be behind the inter-
provincially varying trends in oxycodone use from 2011
onward.
While a large proportion of recent policy and media
attention regarding POA use and harm in Canada has
focused on Oxycontin® and its delisting, this perspective
may be unduly narrow and limited, as several other fac-
tors could have contributed to the reductions in ‘strong
opioid’ dispensing. For example, the extensive media at-
tention on POA related harm, the new National Opioid
Guidelines, or widely publicized coroners’ investigations
into PO-related overprescribing and deaths (e.g., in
Ontario) could have all resulted in more cautious or re-
strained POA prescribing by physicians [12,21,45]. While
none of the above cited events technically forced reduc-
tions in POA prescribing, these could have entailed an
overall ‘chilling effect’ described in other contexts, mak-
ing physicians more hesitant or unwilling to prescribe
POAs [46-48]. Dasgupta et al. examined the levels and
potential impact of media reporting on POA abuse and
found a positive correlation [45]; however, in the distinct
context of the present study, the impact of media report-
ing may have contributed to lesser levels of POA
prescribing.
Importantly, however, we also observed increases in
select other ‘strong opioids’ – specifically, fentanyl and
hydromorphone – in most provinces occurring in paral-
lel to the decreases in oxycodone dispensing. These
developments could point to a possible (partial) ‘substi-
tution effect’, i.e. that other ‘strong opioids’ were increas-
ingly prescribed where oxycodone utilization has been
reduced, as possible development raised as a concern
when the broad-based Oxycontin® delisting occurred
[24,25,49]. ‘Substitution effects’ have been described for
both POAs and non-POA psychotropic medications sub-
sequent to the implementation of tighter regulatorycontrols or monitoring, entailing shifts in both utilization
and harm (e.g., in morbidity or mortality) [50-52].
As a limitation of these analyses, community (i.e., re-
tail pharmacy) dispensing accounts only for a part (yet
the large majority) of POA dispensing in Canada; in
addition, dispensing amounts do not necessarily equate
consumption data yet are a best available and closest
measurable proxy indicator of POA consumption.
Conclusions
In sum, both the key drivers behind, yet especially vari-
ous key consequences of the observed recent changes in
POA dispensing in Canada, need to be systematically
evaluated from both clinical and population health per-
spectives, also given the strong evidence that POA
dispensing levels are closely associated with levels of
key harm (e.g., non-medical prescription opioid use
(NMPOU) morbidity, mortality) indicators [14-16,53].
For example, recent data have found a significant reduc-
tion in non-medical POA use in the general Ontario
adult population, which may be related to recent reduc-
tions in overall POA availability [54]. At the same time,
we note the observed key changes in POA dispensing
levels occurred prior to the launch of a Canadian ‘Na-
tional Prescription Drug Use Strategy’ – a package of
recommendations and measures aimed at the preven-
tion, surveillance, treatment and enforcement of POA-
related problems assembled by various governmental
agencies and non-governmental stakeholders – in 2013
[55]. While the implementation and potential effects of
these proposed measures remain to be assessed, they
could not have had any impact on the data presented
here, as the study period ended before these interven-
tions were announced or implemented.
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